Work

Mutual Waxing and Waning—A Novel Nano‐Biocomposite Harnesses the Lactate Gradient to Enhance Cuproptosis and Anti‐Tumor Immunity

Year: 2026
Type: article
Abstract: Modifying the lactate gradient in tumors can induce acidosis and improve the immunosuppressive microenvironment. However, the therapeutic benefit is offset by compensatory metabolic adaptations and the inability of small-molecule drugs to regulate the gradient throughout the tumor tissue. This study developed a novel nano-biocomposite (LOB@CDSH) that combines cuproptosis to damage mitochondria and cut off energy supply, thereby improving the therapeutic outcome of acidosis induction. Simultaneously, it utilizes the invasive and tumor-colonizing capabilities of engineered bacteria to efficiently reduce lactate levels within tumor tissues. The MCT4 inhibitor syrosingopine (Syro) was loaded into a reactive oxygen species-responsive copper-based metal-organic framework (Cu-DTA) and coated with hyaluronic acid (HA) to form Cu-DTA@Syro@HA (CDSH). Syro inhibits lactate efflux, leading to intracellular lactate accumulation and acidosis. This promotes mitochondrial metabolism and induces lactylation modification of methyltransferase-like 16 (METTL16), thereby upregulating the expression of ferredoxin 1 (FDX1) to enhance cuproptosis. Lactate oxidase (LOX)-engineered Escherichia coli BL21 (LOB) serves as a carrier to deliver CDSH to the tumor site, where it proliferates, disseminates, and continuously expresses LOX to deplete lactate in the tumor microenvironment, thereby alleviating lactate-mediated immunosuppression. The aforementioned nano-biocomposite provides a reciprocally modulating strategy for lactate metabolism, offering a novel approach for tumor immunotherapy.
Institution: Shandong University
Language: English
Open Access status: bronze
OpenAlex ID: W4414171081
FWCI:
Cites: 65
Cited by:
Related to: 10